Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642155 | 0.81 | TSHR (0.45) | TSHRACHECA1CA2CA9 | |
| SCHEMBL8999536 | 0.81 | TSHR (0.45) | TSHRACHECA1CA2CA9 | |
| SCHEMBL6508099 | 0.81 | TSHR (0.45) | TSHRACHECA1CA2CA9 | |
| SCHEMBL29726981 | 0.81 | TSHR (0.45) | TSHRACHECA1CA2CA9 | |
| SCHEMBL18154498 | 0.80 | PTPRC (0.37) | NPC1RAB9ASMN1; SMN2TSHRCASP3 | |
| SCHEMBL24589026 | 0.77 | — | — | |
| SCHEMBL14951394 | 0.77 | MAPK1 (0.41) | NPC1RAB9ASMN1; SMN2GAAIDO1 | |
| SCHEMBL19429151 | 0.76 | PTGS2 (0.41) | SMN1; SMN2HTR7ALDH1A1HPGD | |
| SCHEMBL197690 | 0.75 | ACHE (0.64) | NPC1RAB9ASMN1; SMN2TSHRACHE | |
| SCHEMBL30169568 | 0.75 | ACHE (0.64) | NPC1RAB9ASMN1; SMN2TSHRACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737815-B1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-7981907-B2 | Thio-substituted biarylmethanesulfinyl derivatives | CEPHALON, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | CEPHALON, INC. (US) | 2009-03-05 | — | — | US | disclosed |
| US-7449481-B2 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | CEPHALON, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| CN-1997628-A | Sulfur-substituted diarylmethanesulfinyl derivatives | CEPHALON INC (US) | 2007-07-11 | — | — | CN | disclosed |
| EP-1737815-A1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20050245747-A1 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | CEPHALON, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005100308-A1 | THIO-SUBSTITUTED BIARYL-METHANESULFINYL DERIVATIVES | CEPHALON, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1586559-A1 | Biaryl-methanethio-, -sulphinyl- and sulphonyl derivatives | CEPHALON, INC. (US) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062284-A1 | Thio-Substituted Biarylmethanesulfinyl Derivatives | AANAT, SNCA, NAT1 | NPC1 1542/4885RAB9A 2634/4885SMN1; SMN2 685/4885 |
| US-20050245747-A1 | e.g. 2-[2-(5-chloro-benzo[b]thiophen-2-yl)-phenylmethanesulfinyl]-acetamide; autoimmune disorders, antidepressant; narcolepsy, Parkinson's, Alzheimer's disease; attention deficit hyperactivity disorder; sleep disorder, fatigue | TPH2, TPH1, AANAT | NPC1 1908/4885RAB9A 2368/4885SMN1; SMN2 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.